Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
Clinical trial NCT03173950 · TERMINATED
Trial details
- NCT number
- NCT03173950
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-13
- Primary completion
- 2025-06-23
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.